Self-Propelled Gemini-like LMWH-Scaffold Nanodrugs for Overall Tumor Microenvironment Manipulation via Macrophage Reprogramming and Vessel Normalization
Source abstract
Abstract
Angiogenesis is the hallmark of melanoma that nurtures the tumor microenvironment (TME) for rapid tumor progression. Vessel normalization could benefit melanoma treatment through TME reconstruction, while its limited duration and extent are still the drag. Herein, two kinds of look-like nanodrugs, called Gemini-like nanodrugs (GLnano), were constructed separately with the same scaffold of antiangiogenic low molecular weight heparin (LMWH) and mixed upon administration in vivo. For one, doxorubicin (DOX) was encapsulated into LMWH-chrysin nanodrug (LCY) with DSPE-PEG-anisamide decoration (D-LCA nanodrugs) for active targeting and direct cell killing toward melanoma cells. For another, matrix metalloproteinases (MMPs)-sensitive peptide was conjugated to LMWH to encapsulate celecoxib (Cel) (C-Lpep nanodrugs), disassembling in TME by MMPs and releasing Cel for M2-to-M1 reprogramming of tumor-associated macrophages. Our results showed that GLnano could remarkably elongate the vessel normalization window up to 12 days with the highest pericyte coverage of nearly 75%, compared to only 4 days by LCY monotherapy. Furthermore, GLnano could spontaneously form the “treatment-delivery” loop to promote nanodrugs toward deep tumor regions, leading to a potent tumor inhibition, metastasis prevention, and overall TME improvements.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoplatforms for cancer theranostics · Immune cells in cancer · Immunotherapy and Immune Responses
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Druggability of Biopharmaceuticals, Department of Pharmaceutics, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China
Funding
Ministry of Education of the People's Republic of China · Government of Jiangsu Province · National Natural Science Foundation of China · State Key Laboratory of Natural Medicines, China Pharmaceutical University · Jiangsu Key Laboratory of Drugability of Biopharmaceuticals, China Pharmaceutical University
References (52)
Show source-provided references
1. 10.1111/pcmr.1273610.1111/pcmr.12736 ↗
2. 10.1038/nrdp.2015.310.1038/nrdp.2015.3 ↗
3. 10.1021/acs.molpharmaceut.7b0047510.1021/acs.molpharmaceut.7b00475 ↗
4. 10.1016/j.phrs.2017.05.00410.1016/j.phrs.2017.05.004 ↗
5. 10.1126/sciadv.170135010.1126/sciadv.1701350 ↗
6. 10.1016/S0140-6736(15)01088-010.1016/S0140-6736(15)01088-0 ↗
7. 10.1002/med.2145210.1002/med.21452 ↗
8. 10.1146/annurev-physiol-020518-11470010.1146/annurev-physiol-020518-114700 ↗
9. 10.1021/acs.nanolett.5b0307310.1021/acs.nanolett.5b03073 ↗
10. 10.1038/nrclinonc.2018.2910.1038/nrclinonc.2018.29 ↗
11. 10.1038/nri.2017.14510.1038/nri.2017.145 ↗
12. 10.2174/138920021766616063020360010.2174/1389200217666160630203600 ↗
13. 10.1158/1078-0432.CCR-16-312210.1158/1078-0432.CCR-16-3122 ↗
14. 10.1016/j.cell.2010.03.01410.1016/j.cell.2010.03.014 ↗
15. 10.3389/fonc.2018.0000310.3389/fonc.2018.00003 ↗
16. 10.1021/acs.nanolett.7b0375610.1021/acs.nanolett.7b03756 ↗
17. 10.1038/nature1349010.1038/nature13490 ↗
18. 10.1038/nrclinonc.2016.21710.1038/nrclinonc.2016.217 ↗
19. 10.1038/cr.2015.6810.1038/cr.2015.68 ↗
20. 10.3389/fimmu.2019.0179910.3389/fimmu.2019.01799 ↗
21. 10.1038/s41467-018-03225-910.1038/s41467-018-03225-9 ↗
22. 10.1016/j.ccr.2010.11.00910.1016/j.ccr.2010.11.009 ↗
23. 10.2147/DDDT.S6630210.2147/DDDT.S66302 ↗
24. 10.1189/jlb.120982110.1189/jlb.1209821 ↗
25. 10.1016/j.ajps.2018.07.00310.1016/j.ajps.2018.07.003 ↗
26. 10.1039/C8BM01350K10.1039/C8BM01350K ↗
27. 10.7150/thno.2167410.7150/thno.21674 ↗
28. 10.1039/C7NR09612G10.1039/C7NR09612G ↗
29. 10.1021/nn400548g10.1021/nn400548g ↗
30. 10.1021/acs.nanolett.8b0107110.1021/acs.nanolett.8b01071 ↗
31. 10.1021/nn700040t10.1021/nn700040t ↗
32. 10.1021/acsnano.8b0288110.1021/acsnano.8b02881 ↗
33. 10.1016/j.biomaterials.2013.01.04210.1016/j.biomaterials.2013.01.042 ↗
34. 10.1016/j.biomaterials.2011.06.02410.1016/j.biomaterials.2011.06.024 ↗
35. 10.1016/j.jconrel.2015.10.04010.1016/j.jconrel.2015.10.040 ↗
36. 10.1007/s10555-018-9740-210.1007/s10555-018-9740-2 ↗
37. 10.1016/j.ccell.2017.10.00310.1016/j.ccell.2017.10.003 ↗
38. 10.1007/s00262-009-0747-y10.1007/s00262-009-0747-y ↗
39. 10.1038/nature1182410.1038/nature11824 ↗
40. 10.1038/nature0966610.1038/nature09666 ↗
41. 10.1016/j.smim.2018.02.00210.1016/j.smim.2018.02.002 ↗
42. 10.1038/ncb333010.1038/ncb3330 ↗
43. 10.1038/ni.383610.1038/ni.3836 ↗
44. 10.1126/scitranslmed.aak967910.1126/scitranslmed.aak9679 ↗
45. 10.1007/978-3-319-22539-5_810.1007/978-3-319-22539-5_8 ↗
46. 10.1002/cam4.114010.1002/cam4.1140 ↗
47. 10.1021/acsami.5b0315010.1021/acsami.5b03150 ↗
48. 10.1016/j.trecan.2018.02.01010.1016/j.trecan.2018.02.010 ↗
49. 10.1002/ajh.2174510.1002/ajh.21745 ↗
50. 10.1016/S0002-9440(10)63540-710.1016/S0002-9440(10)63540-7 ↗
51. 10.1038/nrm317610.1038/nrm3176 ↗
52. 10.1152/ajpheart.00290.201810.1152/ajpheart.00290.2018 ↗